Sign in Subscribe
Class action lawsuits

Securities Class Action Lawsuit Filed Against Replimune Group, Inc.

Strategic Insights

— 1 min read

Replimune Group, Inc.'s (NASDAQ: REPL) securities class action lawsuit alleges that the company made false and misleading statements about the prospects of its IGNYTE trial, which resulted in the U.S. Food and Drug Administration ("FDA") deeming the trial inadequate and not well-controlled. The lawsuit claims that investors suffered damages when the true details of the trial's issues entered the market.

Key Takeaways:

  • The lawsuit was filed between November 22, 2024, and July 21, 2025, and investors who purchased Replimune securities during this period may be entitled to compensation.
  • The class action lawsuit was first filed by the Rosen Law Firm, a global investor rights law firm.
  • The lead plaintiff deadline is September 22, 2025, and investors who wish to serve as lead plaintiff must move the Court by this date.
  • The Rosen Law Firm has a track record of success in securities class actions, with over $438 million in recoveries for investors in 2019 alone.
  • The lawsuit claims that Replimune's defendants recklessly overstated the IGNYTE trial's prospects, given material issues that they knew or should have known of.
  • The lawsuit alleges that investors suffered damages when the true details of the trial's issues entered the market.

Statistics:

  • The lawsuit was filed between November 22, 2024, and July 21, 2025.
  • The lead plaintiff deadline is September 22, 2025.
  • The Rosen Law Firm has secured over $438 million in recoveries for investors in 2019.
  • The lawsuit claims that investors suffered damages when the true details of the trial's issues entered the market.

Sources:

  • "Replimune Securities Class Action Lawsuit." Rosen Law Firm, August 6, 2025.
  • "Class Action Lawsuit Filed." Newsfile Corp., August 6, 2025.

Read more